OLIN Corp. 10-Q Summary: Quarter Ended September 30, 1997
Business Context and Reporting Period
This is an unaudited quarterly report (Form 10-Q) for OLIN Corporation, a diversified chemical and metals company, for the period ended September 30, 1997. The company operates primarily in Chemicals and Metals & Ammunition segments. Significant corporate actions during the period included the completion of the Niachlor acquisition, the spin-off of the Ordnance and Aerospace businesses (Primex) in late 1996, and the announced sale of specific surfactant and glycol businesses to BASF.
Key Financial Metrics
| Metric (in millions) | Q3 1997 | Q3 1996 | 9M 1997 | 9M 1996 |
|---|---|---|---|---|
| Sales | $607.9 | $652.0 | $1,831.5 | $2,046.6 |
| Operating Income | $58.7 | $64.3 | $178.8 | $217.6 |
| Net Income | $38.0 | $37.8 | $118.4 | $134.5 |
| Diluted EPS | $0.75 | $0.70 | $2.30 | $2.53 |
| Cash & Equivalents | $36.0 | $5.3 | $36.0 | $5.3 |
| Short-term Debt | $7.2 | $138.8 | $7.2 | $138.8 |
| Long-term Debt | $268.0 | $276.3 | $268.0 | $276.3 |
Liquidity & Margins: Gross margin for the nine months ended September 30, 1997, was approximately 23% ($420.1 million on $1,831.5 million sales). The company maintained $258 million in committed credit facilities, all of which were available as of September 30, 1997. Debt-to-total capitalization decreased to 23.5% from 33.5% in the prior year.
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 7% in Q3 and 11% for the nine-month period compared to 1996. This decline is largely attributed to the sale of the isocyanates business in December 1996. On a comparable basis excluding the sold business, sales increased 4% in Q3 due to volume growth and the Niachlor acquisition, offset by lower selling prices.
- Profitability: Net income remained relatively stable in Q3 ($38.0M vs $37.8M) despite lower sales, driven by cost controls and the absence of discontinued operations losses seen in 1996. Operating income declined 9% in Q3 and 18% for the nine-month period.
- Cash Flow: Net cash provided by operating activities collapsed to $0.5 million for the nine months ended September 30, 1997, compared to $133.1 million in 1996. This was caused by a significant increase in working capital investment (receivables and inventory) and lower operating income.
- Balance Sheet: Cash and cash equivalents dropped from $523.5 million at year-end 1996 to $36.0 million at September 30, 1997. This reduction was driven by $127.1 million in share repurchases, $138.5 million in long-term debt repayments, and $116.4 million in taxes paid on the prior year's isocyanates sale.
Outlook, Risks, and Management Commentary
- Strategic Divestitures: In October 1997, the company announced the sale of its surfactants, fluids, and glycol businesses to BASF, expected to close by November 1997. Management does not expect this to materially affect results of operations.
- Capital Expenditures: Capital spending for the full year 1997 is estimated to increase 20-25% over 1996 to expand capacity in Chemicals, including new facilities in Belgium and Rhode Island.
- Environmental Contingencies: The company faces significant environmental liabilities. Reserves for future expenditures were $135 million at September 30, 1997. Annual cash outlays for environmental activities are expected to range between $75 million and $90 million for the next several years. Management notes that outcomes are subject to uncertainty and unfavorable resolutions are possible.
- Segment Performance: The Chemicals segment saw operating income rise 4% for the nine months on a continuing business basis, driven by Biocides and Hydrazine/Propellants, though Microelectronic Materials faced headwinds. The Metals & Ammunition segment saw slightly lower sales and income due to reduced military ammunition shipments.
Investor Verification Checklist
- Working Capital Trends: Verify the sustainability of the sharp increase in receivables and inventory, which severely impacted operating cash flow.
- Environmental Reserves: Monitor the $135 million environmental liability reserve and the potential for future charges given the uncertainty of remediation costs.
- Share Repurchase Program: Confirm the remaining authorization and impact of the $127 million stock buyback on future liquidity.
- BASF Transaction: Track the completion of the sale to BASF and the terms of the subsequent supply agreement at the Doe Run facility.
- Capital Project Execution: Assess the timeline and cost of the new Microelectronic Materials and Biocides facilities scheduled for completion in 1998 and 2000.